(March 2020) -- To speed treatments, global biotech leader CSL is lend ingthe company’s expertise in science and manufacturing to address the recent coronavirus global pandemic. The company is exploring development of a hyperimmune serum
that could be derived from the blood plasma of people who have recovered
from coronavirus. Once an adequate number of recovered patients is
identified, it’s our hope that CSL could begin to collect their plasma
and create a hyperimmune serum enriched with COV-19 antibodies to use as
a therapy.
Though more research and testing is necessary, it’s believed that antibodies found in the plasma of now-healthy COVID-19 patients could potentially be used to boost the immune response of those who are struggling with the infection. By now it is well known that coronavirus causes mild flu-like symptoms in many, but others who are older than 60 or have additional medical conditions are at high risk of fatal complications.
[READ MORE]
Though more research and testing is necessary, it’s believed that antibodies found in the plasma of now-healthy COVID-19 patients could potentially be used to boost the immune response of those who are struggling with the infection. By now it is well known that coronavirus causes mild flu-like symptoms in many, but others who are older than 60 or have additional medical conditions are at high risk of fatal complications.
